This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacqueline, C.
Right arrow Articles by Bugnon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacqueline, C.
Right arrow Articles by Bugnon, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2002, p. 3706-3711, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3706-3711.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model

Cédric Jacqueline, Eric Batard, Lucia Perez, David Boutoille, Antoine Hamel, Jocelyne Caillon, Marie-France Kergueris, Gilles Potel,* and Denis Bugnon

Laboratoire d'Antibiologie (UPRES EA-1156), Faculté de Médecine, 44035 Nantes, Cedex 01, France

Received 8 April 2002/ Returned for modification 20 May 2002/ Accepted 28 August 2002

Linezolid is the first drug issued from the oxazolidinones, a novel class of antimicrobial agents with potent activity against gram-positive pathogens. A rabbit endocarditis model was used to compare the in vivo activities of different linezolid regimens mimicking intermittent dosing of 10 mg/kg of body weight every 12 h for 5 days or continuous (constant-rate) infusion of a daily dose of 20 mg/kg (for 5 days) or 40 mg/kg (for 3 and 5 days) and the activities of intermittent dosing and continuous infusion of vancomycin (for 5 days). The in vivo activities of these regimens were tested against three strains of methicillin-resistant Staphylococcus aureus. A human-like pharmacokinetic simulation was used for linezolid in order to improve the extrapolation of the results to human therapy. All linezolid regimens significantly reduced the numbers of S. aureus cells in aortic valve vegetations compared to the numbers in the control groups. Linezolid intermittent dosing had an in vivo bacteriostatic effect. Switching from intermittent dosing to continuous infusion (at the same dose) led to in vivo bactericidal activity, with a decrease of at least 3 log10 CFU/g of vegetation compared to the counts for the controls. After 5 days of treatment, continuous infusion of linezolid (corresponding to a daily dose of 40 mg/kg in humans) seemed to be at least as effective as vancomycin against the three strains. No resistant variant was isolated from the vegetations during any of the treatments. These data suggest that continuous infusion of linezolid could be an appropriate alternative to the use of glycopeptides for the treatment of severe methicillin-resistant S. aureus infections.

* Corresponding author. Mailing address: Laboratoire d'Antibiologie, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes, Cedex 01, France. Phone and Fax: (33) 240-41-2854. E-mail: gpotel{at}sante.univ-nantes.fr.

Antimicrobial Agents and Chemotherapy, December 2002, p. 3706-3711, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3706-3711.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lovering, A. M., Le Floch, R., Hovsepian, L., Stephanazzi, J., Bret, P., Birraux, G., Vinsonneau, C. (2009). Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 63: 553-559 [Abstract] [Full Text]  
  • Tsaganos, T., Skiadas, I., Koutoukas, P., Adamis, T., Baxevanos, N., Tzepi, I., Pelekanou, A., Giamarellos-Bourboulis, E. J., Giamarellou, H., Kanellakopoulou, K. (2008). Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 62: 381-383 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Hamel, A., Bugnon, D., Ge, J. Y., Potel, G. (2007). In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 51: 3397-3400 [Abstract] [Full Text]  
  • Boak, L. M., Li, J., Rayner, C. R., Nation, R. L. (2007). Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro Model. Antimicrob. Agents Chemother. 51: 1287-1292 [Abstract] [Full Text]  
  • Falagas, M. E., Manta, K. G., Ntziora, F., Vardakas, K. Z. (2006). Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58: 273-280 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Grossi, O., Le Mabecque, V., Miegeville, A.-F., Bugnon, D., Batard, E., Potel, G. (2006). In Vitro and In Vivo Assessment of Linezolid Combined with Ertapenem: a Highly Synergistic Combination against Methicillin-Resistant Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2547-2549 [Abstract] [Full Text]  
  • Athanassopoulos, G., Pefanis, A., Sakka, V., Iliopoulos, D., Perrea, D., Giamarellou, H. (2006). Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to Streptococcus oralis or Enterococcus faecalis. Antimicrob. Agents Chemother. 50: 654-657 [Abstract] [Full Text]  
  • Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., Caillon, J. (2005). In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 45-51 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J. (2004). Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 48: 4665-4672 [Abstract] [Full Text]  
  • Liu, Y. Q., Zhang, Y. Z., Gao, P. J. (2004). Novel Concentration-Killing Curve Method for Estimation of Bactericidal Potency of Antibiotics in an In Vitro Dynamic Model. Antimicrob. Agents Chemother. 48: 3884-3891 [Abstract] [Full Text]  
  • Mogenet, I., Raetz-Dillon, S., Canonge, J.-M., Archambaud, M., Bonnet, E. (2004). Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid. The Annals of Pharmacotherapy 38: 986-988 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»